Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer Article Swipe
Raquel De Souza
,
Payam Zahedi
,
Eduardo H. Moriyama
,
Christine Allen
,
Brian C. Wilson
,
Micheline Piquette‐Miller
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.c.6532133.v1
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.1158/1535-7163.c.6532133.v1
Ovarian cancer is known as the silent killer for being asymptomatic until late stages. Current first-line treatment consists of debulking surgery followed by i.v. chemotherapeutics administered intermittently, which leads to insufficient drug concentrations at tumor sites, accelerated tumor proliferation rates, and drug resistance, resulting in an overall median survival of only 2 to 4 years. For these reasons, more effective treatment strategies must be developed. We have investigated a localized, continuous chemotherapy approach in tumor models of human and murine ovarian cancers using the antineoplastic agent docetaxel. We show here that continuous docetaxel therapy is considerably more efficacious than intermittent therapy, resulting in a greater decrease in tumor burden and ascites fluid accumulation. Immunohistochemical analyses show that continuous chemotherapy abrogates tumor cell proliferation and angiogenesis to the tumor microenvironment, leading to greater tumor cell death than intermittent docetaxel therapy. Overall, our results show greater therapeutic advantages of continuous over intermittent chemotherapy in the treatment of ovarian cancer. Mol Cancer Ther; 9(6); 1820–30. ©2010 AACR.
Related Topics
Concepts
Metadata
- Type
- preprint
- Language
- en
- Landing Page
- https://doi.org/10.1158/1535-7163.c.6532133.v1
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4361813598
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4361813598Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1158/1535-7163.c.6532133.v1Digital Object Identifier
- Title
-
Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian CancerWork title
- Type
-
preprintOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-03-31Full publication date if available
- Authors
-
Raquel De Souza, Payam Zahedi, Eduardo H. Moriyama, Christine Allen, Brian C. Wilson, Micheline Piquette‐MillerList of authors in order
- Landing page
-
https://doi.org/10.1158/1535-7163.c.6532133.v1Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.1158/1535-7163.c.6532133.v1Direct OA link when available
- Concepts
-
Docetaxel, Ovarian cancer, Medicine, Chemotherapy, Debulking, Oncology, Internal medicine, Cancer, Angiogenesis, Asymptomatic, Ascites, Tumor microenvironment, Cancer researchTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4361813598 |
|---|---|
| doi | https://doi.org/10.1158/1535-7163.c.6532133.v1 |
| ids.doi | https://doi.org/10.1158/1535-7163.c.6532133.v1 |
| ids.openalex | https://openalex.org/W4361813598 |
| fwci | |
| type | preprint |
| title | Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10550 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2743 |
| topics[0].subfield.display_name | Reproductive Medicine |
| topics[0].display_name | Ovarian cancer diagnosis and treatment |
| topics[1].id | https://openalex.org/T11829 |
| topics[1].field.id | https://openalex.org/fields/26 |
| topics[1].field.display_name | Mathematics |
| topics[1].score | 0.9911999702453613 |
| topics[1].domain.id | https://openalex.org/domains/3 |
| topics[1].domain.display_name | Physical Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2611 |
| topics[1].subfield.display_name | Modeling and Simulation |
| topics[1].display_name | Mathematical Biology Tumor Growth |
| topics[2].id | https://openalex.org/T11287 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.989300012588501 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Cancer Genomics and Diagnostics |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2781190966 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9372345209121704 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q420436 |
| concepts[0].display_name | Docetaxel |
| concepts[1].id | https://openalex.org/C2780427987 |
| concepts[1].level | 3 |
| concepts[1].score | 0.8099374771118164 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q172341 |
| concepts[1].display_name | Ovarian cancer |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.7550631761550903 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2776694085 |
| concepts[3].level | 2 |
| concepts[3].score | 0.7386035323143005 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[3].display_name | Chemotherapy |
| concepts[4].id | https://openalex.org/C2781100745 |
| concepts[4].level | 4 |
| concepts[4].score | 0.6884440779685974 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1977435 |
| concepts[4].display_name | Debulking |
| concepts[5].id | https://openalex.org/C143998085 |
| concepts[5].level | 1 |
| concepts[5].score | 0.521319568157196 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[5].display_name | Oncology |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.50899338722229 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C121608353 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4809807538986206 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[7].display_name | Cancer |
| concepts[8].id | https://openalex.org/C2780394083 |
| concepts[8].level | 2 |
| concepts[8].score | 0.4792728126049042 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q539568 |
| concepts[8].display_name | Angiogenesis |
| concepts[9].id | https://openalex.org/C2777910003 |
| concepts[9].level | 2 |
| concepts[9].score | 0.45215344429016113 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q1707292 |
| concepts[9].display_name | Asymptomatic |
| concepts[10].id | https://openalex.org/C2780496750 |
| concepts[10].level | 2 |
| concepts[10].score | 0.4453592300415039 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q193889 |
| concepts[10].display_name | Ascites |
| concepts[11].id | https://openalex.org/C2776107976 |
| concepts[11].level | 3 |
| concepts[11].score | 0.4154198467731476 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q1786433 |
| concepts[11].display_name | Tumor microenvironment |
| concepts[12].id | https://openalex.org/C502942594 |
| concepts[12].level | 1 |
| concepts[12].score | 0.36434677243232727 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[12].display_name | Cancer research |
| keywords[0].id | https://openalex.org/keywords/docetaxel |
| keywords[0].score | 0.9372345209121704 |
| keywords[0].display_name | Docetaxel |
| keywords[1].id | https://openalex.org/keywords/ovarian-cancer |
| keywords[1].score | 0.8099374771118164 |
| keywords[1].display_name | Ovarian cancer |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.7550631761550903 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/chemotherapy |
| keywords[3].score | 0.7386035323143005 |
| keywords[3].display_name | Chemotherapy |
| keywords[4].id | https://openalex.org/keywords/debulking |
| keywords[4].score | 0.6884440779685974 |
| keywords[4].display_name | Debulking |
| keywords[5].id | https://openalex.org/keywords/oncology |
| keywords[5].score | 0.521319568157196 |
| keywords[5].display_name | Oncology |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.50899338722229 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/cancer |
| keywords[7].score | 0.4809807538986206 |
| keywords[7].display_name | Cancer |
| keywords[8].id | https://openalex.org/keywords/angiogenesis |
| keywords[8].score | 0.4792728126049042 |
| keywords[8].display_name | Angiogenesis |
| keywords[9].id | https://openalex.org/keywords/asymptomatic |
| keywords[9].score | 0.45215344429016113 |
| keywords[9].display_name | Asymptomatic |
| keywords[10].id | https://openalex.org/keywords/ascites |
| keywords[10].score | 0.4453592300415039 |
| keywords[10].display_name | Ascites |
| keywords[11].id | https://openalex.org/keywords/tumor-microenvironment |
| keywords[11].score | 0.4154198467731476 |
| keywords[11].display_name | Tumor microenvironment |
| keywords[12].id | https://openalex.org/keywords/cancer-research |
| keywords[12].score | 0.36434677243232727 |
| keywords[12].display_name | Cancer research |
| language | en |
| locations[0].id | doi:10.1158/1535-7163.c.6532133.v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.1158/1535-7163.c.6532133.v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5057874572 |
| authorships[0].author.orcid | https://orcid.org/0000-0001-5502-6329 |
| authorships[0].author.display_name | Raquel De Souza |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Raquel De Souza |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5033070603 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-6636-4534 |
| authorships[1].author.display_name | Payam Zahedi |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Payam Zahedi |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5042454780 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Eduardo H. Moriyama |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Eduardo H. Moriyama |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5086834252 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-4916-3965 |
| authorships[3].author.display_name | Christine Allen |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Christine J. Allen |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5080602355 |
| authorships[4].author.orcid | https://orcid.org/0000-0001-5543-666X |
| authorships[4].author.display_name | Brian C. Wilson |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Brian C. Wilson |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5013796776 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-3847-8224 |
| authorships[5].author.display_name | Micheline Piquette‐Miller |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Micheline Piquette-Miller |
| authorships[5].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.1158/1535-7163.c.6532133.v1 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Data from Continuous Docetaxel Chemotherapy Improves Therapeutic Efficacy in Murine Models of Ovarian Cancer |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10550 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2743 |
| primary_topic.subfield.display_name | Reproductive Medicine |
| primary_topic.display_name | Ovarian cancer diagnosis and treatment |
| related_works | https://openalex.org/W2357951126, https://openalex.org/W2080820783, https://openalex.org/W2406404783, https://openalex.org/W2315587357, https://openalex.org/W2133480631, https://openalex.org/W2065800215, https://openalex.org/W3032029751, https://openalex.org/W4361813211, https://openalex.org/W2138124620, https://openalex.org/W4361813598 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.1158/1535-7163.c.6532133.v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.1158/1535-7163.c.6532133.v1 |
| primary_location.id | doi:10.1158/1535-7163.c.6532133.v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.1158/1535-7163.c.6532133.v1 |
| publication_date | 2023-03-31 |
| publication_year | 2023 |
| referenced_works_count | 0 |
| abstract_inverted_index.2 | 51 |
| abstract_inverted_index.4 | 53 |
| abstract_inverted_index.a | 68, 103 |
| abstract_inverted_index.We | 65, 87 |
| abstract_inverted_index.an | 45 |
| abstract_inverted_index.as | 4 |
| abstract_inverted_index.at | 33 |
| abstract_inverted_index.be | 63 |
| abstract_inverted_index.by | 22 |
| abstract_inverted_index.in | 44, 73, 102, 106, 151 |
| abstract_inverted_index.is | 2, 94 |
| abstract_inverted_index.of | 18, 49, 76, 146, 154 |
| abstract_inverted_index.to | 29, 52, 125, 130 |
| abstract_inverted_index.For | 55 |
| abstract_inverted_index.Mol | 157 |
| abstract_inverted_index.and | 40, 78, 109, 123 |
| abstract_inverted_index.for | 8 |
| abstract_inverted_index.our | 140 |
| abstract_inverted_index.the | 5, 83, 126, 152 |
| abstract_inverted_index.cell | 121, 133 |
| abstract_inverted_index.drug | 31, 41 |
| abstract_inverted_index.have | 66 |
| abstract_inverted_index.here | 89 |
| abstract_inverted_index.i.v. | 23 |
| abstract_inverted_index.late | 12 |
| abstract_inverted_index.more | 58, 96 |
| abstract_inverted_index.must | 62 |
| abstract_inverted_index.only | 50 |
| abstract_inverted_index.over | 148 |
| abstract_inverted_index.show | 88, 115, 142 |
| abstract_inverted_index.than | 98, 135 |
| abstract_inverted_index.that | 90, 116 |
| abstract_inverted_index.9(6); | 160 |
| abstract_inverted_index.Ther; | 159 |
| abstract_inverted_index.agent | 85 |
| abstract_inverted_index.being | 9 |
| abstract_inverted_index.death | 134 |
| abstract_inverted_index.fluid | 111 |
| abstract_inverted_index.human | 77 |
| abstract_inverted_index.known | 3 |
| abstract_inverted_index.leads | 28 |
| abstract_inverted_index.these | 56 |
| abstract_inverted_index.tumor | 34, 37, 74, 107, 120, 127, 132 |
| abstract_inverted_index.until | 11 |
| abstract_inverted_index.using | 82 |
| abstract_inverted_index.which | 27 |
| abstract_inverted_index.Cancer | 158 |
| abstract_inverted_index.burden | 108 |
| abstract_inverted_index.cancer | 1 |
| abstract_inverted_index.killer | 7 |
| abstract_inverted_index.median | 47 |
| abstract_inverted_index.models | 75 |
| abstract_inverted_index.murine | 79 |
| abstract_inverted_index.rates, | 39 |
| abstract_inverted_index.silent | 6 |
| abstract_inverted_index.sites, | 35 |
| abstract_inverted_index.years. | 54 |
| abstract_inverted_index.©2010 | 162 |
| abstract_inverted_index.Current | 14 |
| abstract_inverted_index.ascites | 110 |
| abstract_inverted_index.cancer. | 156 |
| abstract_inverted_index.cancers | 81 |
| abstract_inverted_index.greater | 104, 131, 143 |
| abstract_inverted_index.leading | 129 |
| abstract_inverted_index.ovarian | 80, 155 |
| abstract_inverted_index.overall | 46 |
| abstract_inverted_index.results | 141 |
| abstract_inverted_index.stages. | 13 |
| abstract_inverted_index.surgery | 20 |
| abstract_inverted_index.therapy | 93 |
| abstract_inverted_index.Overall, | 139 |
| abstract_inverted_index.analyses | 114 |
| abstract_inverted_index.approach | 72 |
| abstract_inverted_index.consists | 17 |
| abstract_inverted_index.decrease | 105 |
| abstract_inverted_index.followed | 21 |
| abstract_inverted_index.reasons, | 57 |
| abstract_inverted_index.survival | 48 |
| abstract_inverted_index.therapy, | 100 |
| abstract_inverted_index.therapy. | 138 |
| abstract_inverted_index.abrogates | 119 |
| abstract_inverted_index.debulking | 19 |
| abstract_inverted_index.docetaxel | 92, 137 |
| abstract_inverted_index.effective | 59 |
| abstract_inverted_index.resulting | 43, 101 |
| abstract_inverted_index.treatment | 16, 60, 153 |
| abstract_inverted_index.1820–30. | 161 |
| abstract_inverted_index.advantages | 145 |
| abstract_inverted_index.continuous | 70, 91, 117, 147 |
| abstract_inverted_index.developed. | 64 |
| abstract_inverted_index.docetaxel. | 86 |
| abstract_inverted_index.first-line | 15 |
| abstract_inverted_index.localized, | 69 |
| abstract_inverted_index.strategies | 61 |
| abstract_inverted_index.accelerated | 36 |
| abstract_inverted_index.efficacious | 97 |
| abstract_inverted_index.resistance, | 42 |
| abstract_inverted_index.therapeutic | 144 |
| abstract_inverted_index.administered | 25 |
| abstract_inverted_index.angiogenesis | 124 |
| abstract_inverted_index.asymptomatic | 10 |
| abstract_inverted_index.chemotherapy | 71, 118, 150 |
| abstract_inverted_index.considerably | 95 |
| abstract_inverted_index.insufficient | 30 |
| abstract_inverted_index.intermittent | 99, 136, 149 |
| abstract_inverted_index.investigated | 67 |
| abstract_inverted_index.accumulation. | 112 |
| abstract_inverted_index.proliferation | 38, 122 |
| abstract_inverted_index.antineoplastic | 84 |
| abstract_inverted_index.concentrations | 32 |
| abstract_inverted_index.intermittently, | 26 |
| abstract_inverted_index.chemotherapeutics | 24 |
| abstract_inverted_index.microenvironment, | 128 |
| abstract_inverted_index.Immunohistochemical | 113 |
| abstract_inverted_index.AACR.</p></div> | 163 |
| abstract_inverted_index.<div>Abstract<p>Ovarian | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 6 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.05834768 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |